Netherlands· NL-ec6e823d7265
Ibrance 100 mg, harde capsule
A palbociclib product containing palbociclib, registered in Netherlands by Pfizer Europe MA EEIG. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Palbociclib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EF01 (palbociclib), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Palbociclib · ATC L01EF01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of palbociclib costs, country by country.
Normalised to the WHO defined daily dose (94 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Palbociclib · price per daily dose (94 mg)
USD · FX 28 Sept 2026
- CH Switzerland$155.65
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- PALBOCICLIB
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Netherlands (NL)
- ATC code
- L01EF01
- ATC class
- Palbociclib
- Defined daily dose
- 94 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/16/1147
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
340 interactions on record for palbociclib.
Graded by severity as the source publishes them — 74 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Palbociclib · interactions on record
340 records
- 74 severe
- 256 moderate
- 10 minor
Most severe, free to view
- LonafarnibA16AX20severe
- BerotralstatB06AC06severe
- ConivaptanC03XA02severe
- KetoconazoleH02CA03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Palbociclib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaIBRANCEPfizer Europe MA EEIG, Bruxelles
- United StatesIbrancePfizer Laboratories Div Pfizer Inc
- United KingdomIbrance 100mg capsulesPfizer Ltd
- SpainIBRANCE 100 MG CAPSULAS DURASPfizer Europe Ma Eeig
- FinlandIBRANCEPfizer Europe MA EEIG
- FranceIBRANCE 100 mg, gélulePFIZER EUROPE MA EEIG (BELGIQUE)
- BelgiumIbrance 100 mgPfizer Europe MA
- IrelandIBRANCE 100 mg hard capsulesPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 15 EEA countries. Names it is sold under:
- Austria · Ibrammaclib
- Bulgaria · Palbociclib
- Denmark · Palbociclib Newbury
- Estonia · Palbociclib
- Finland · Palbociclib Avansor
- United Kingdom (Northern Ireland) · Palbociclib Thornton & Ross
- Greece · Palbociclib Faran
- Croatia · Palbociclib
- Hungary · Palbociclib
- Iceland · Ibrance, Palbociclib Viatris
- Liechtenstein · Ibrance, Palbociclib Viatris
- Malta · Palbociclib, Palbociclib Lotus
- Norway · Ibrance, Palbociclib Newbury
- Poland · Palbociclib Polpharma
- Sweden · Brancen, Brical
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4862be6e-a30f-4df0-b999-335d5dc40c87 GET /v1/drugs/4862be6e-a30f-4df0-b999-335d5dc40c87?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, hard",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Palbociclib",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp117863",
"excipients": [
"AMMONIA (E 527)",
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"GELATINE (E 441)",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ROOD (E 172)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMZETMEELGLYCOLAAT",
"PROPYLEENGLYCOL (E 1520)",
"SCHELLAK GLAZE, GEDEELTELIJK VERESTERD",
"SILICIUMDIOXIDE (E 551)",
"SIMETICON",
"TITAANDIOXIDE (E 171)",
"TITAANDIOXIDE (E 171)",
"WITTE INKT"
],
"substances": [
"PALBOCICLIB"
],
"leaflet_url": null,
"authorised_at": "2016/11/09",
"procedure_number": "EMEA/H/C/003853",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/16/1147",
"additional_monitoring": "N"
}See everything about palbociclib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.